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Abstract
As hospital medical device managers obtain more data, opportunities exist for using the An important aspect of medical equipment management is having an effective battery replacement interval that is cost effective and minimizes potential unexpected failures during use. Despite the best efforts for user education, proper battery life management through appropriate charging of the battery is not always followed in hospital settings. As a result, the life of medical device batteries can vary from the manufacturer specification. Medical device managers have increased access to repair data and other device usage data, including unexpected battery failures. Data analytics and advanced statistical techniques can be used to make informed decisions on how to effectively manage equipment maintenance schedules when battery life does not meet expectations.
Using survival analysis statistical methods on an actual hospital's infusion device lithium battery failure data, this study sought to answer two questions: 1) What is the optimum age at which to replace the infusion device lithium ion battery in use at the facility? 2) Among the batteries in use at the facility, which ones had the shortest and longest lifespans?
To answer these questions, Kaplan-Meier survival analysis and log-rank test, as well as the LIFEREG, LIFETEST, and RELIABILITY procedures in SAS statistical analysis software, were used.
Introduction to Survival Analysis
Survival analysis is a family of statistical methods designed for the analysis of duration data (i.e., how long until an event occurs event of interest either occurs or does not occur. This can be illustrated using the example of three patients being studied for time to death from heart failure following heart transplants. Here, the event of interest is patient death due to heart failure, and the maximum time these patients can be observed is 10 years. When one patient dies from heart failure two years into the study, the observation is recorded as an event at two years. Another patient is killed in an automobile accident five years later, and the observation is recorded as censored at five years because the death was not heart related. The final patient lives longer than the 10 years-beyond the period of study-and the observation is recorded as censored at 10 years.
This random variable (time) will take on a probability density function, f(t), to describe the probability of failure past a given time t. The cumulative distribution function, F(t), describes the probability of observing an event at a time less than or equal to t. The cumulative distribution function is defined as
The basic quantity used to describe time-toevent phenomena is the survival function, which is the probability of an individual surviving beyond time t (experiencing the event after time t). 1 It is defined as:
To use the survival analysis functions, data are needed with time to event as the variable of interest. The main difference between survival analysis and other types of data is that the event of interest is not observed in all of the subjects within the observed time period. 2 We only know that at the censored time, the observation has not experienced the event of interest. As a result of this censoring of data, other statistical methods are no longer appropriate.
Kaplan-Meier Survival Analysis
The Kaplan-Meier survival curve is a nonparametric maximum likelihood estimator of the probability of survival in a given length of time, with time taken in multiple small intervals. This method allows the survival function to be calculated. The Kaplan-Meier survival curve is also called "product limit estimate."
The survival probability at any point in time is written as:
where n i is the number of survivors just prior to time t i . If no censoring occurs, all subjects have failed. 3 When there is censoring, n i equals the number of survivors less the number of censored cases (i.e., subjects who were no longer observed at a given time). The number of failed subjects within the same observation period is indicated by d i .
The Kaplan-Meier method can create both a tabular estimate and graphical stairstep curve for use in analysis. If the analysis needed falls within the curve, before the last censored time, it is a simple method to use. To use the Kaplan-Meier method, certain assumptions must be present: censoring is unrelated to either survival or failure, the survival probabilities are the same for all subjects regardless of when the observation period began, and event times are accurately recorded. These minimal assumptions are important because they allow the Kaplan-Meier method to be applied to a range of time-to-event data.
Log-Rank Test
The log-rank test is a nonparametric hypothesis test comparing more than one strata of survival distributions. The log-rank test compares the hazard function estimates of two or more survival groups at each observed time. In other words, this test allows for comparisons of differences in survival times for an event among different groups of observations (e.g., different brands of batteries, differences among batteries from multiple vendors, different battery charging management techniques).
The general form of the test statistic is:
where 
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This test statistic will have a chi-squared distribution with degrees of freedom equal to one less than the number of groups being compared. The null hypothesis for the log-rank test is that all groups have an equal hazard rate/survival distribution. The rejection of the null hypothesis would be that at least one of the survival groups has a different hazard rate/survival distribution. In other words, a rejection of the null hypothesis would result in a conclusion that at least one of the survival groups has a different survival distribution than the other two.
Description of Infusion Pump Battery Data
A total of 442 infusion pumps were in service at the hospital network during the period of study (April 2008 to December 2014). All of the devices were shipped with new batteries from the manufacturer. Many of the devices had battery failures and were replaced as they failed. Due to the manner in which the infusion devices were implemented in the hospital, the battery discharging and recharging management was assumed to be generally equivalent across all devices. The infusion pumps would leave a central distribution point for use in patient care. After the infusion device was no longer needed for patient care, it was returned to the central distribution point, cleaned, and plugged in until it was needed again. According to this strategy, devices were charged partially, but not necessarily fully, between patients. The assumption of generally equal and randomly assigned battery management is important to this analysis. If another facility uses a different battery management strategy that is not equivalent for a group of devices, other survival analysis methods should be used.
The replacement batteries consisted of the infusion device manufacturer's battery (A), and one of two third-party supplier batteries (B or C). Replacement battery selection was based on the availability of the battery at the time it was needed. The total cost difference between the three battery suppliers was minimal (<$7). Of note, although there are other suppliers for the custom battery pack used on the infusion device, only two third-party vendors were used at this facility based on a decision by management. As a result of frequent supplier shortages, batteries were ordered from the supplier that had the quantity in stock needed for replacement. This resulted in a somewhat random distribution of the batteries across the inventory of infusion devices (822 total batteries for the survival analysis, with three part numbers to compare) ( Table 1) . Some of the intravenous pump controllers, as indicated by the control number identification, had more than one battery replacement during the time period of study. Table 2 illustrates the dataset by showing the first 17 observations.
Analysis Comparing Batteries
Initial analysis on the battery data was performed using the Kaplan-Meier plot from the SAS LIFETEST procedure. Table 3 shows that battery B may have censored values that were too high (~87%) to accurately determine whether this battery is different than the others. The overall censored rate was 54%; therefore, any fit of distribution may be underestimated. The Kaplan-Meier graph for the individual batteries is shown in Figure 1 , indicating that a difference in failure rates exists for batteries A and C. The test for equality over the different batteries resulted in rejection of the assumption that all three batteries have equal survival curves (Table 4 ). In particular, because the log-rank test showed a P value <0.0001, we can conclude that at least one battery had a different survival curve than the others. Based on the small sample for battery B and the difference apparent in Figure 1 between batteries A and C, we can conclude that battery C has a lower survival probability than battery A. However, we cannot conclude any difference between batteries A and B.
Analysis Comparing Maintenance Schedules for Battery Replacement
The Kaplan-Meier tabular output for all three batteries combined shows that at three years (1,095 days), the cumulative survival will be approximately 0.72 (Table 5) . This translates to a risk of unexpected battery failure of 28%. At two years (730 days), the survival estimate will be approximately 0.93. A total failure estimate of only 7% would be expected at two years. After the complete inventory of battery C is replaced, another analysis would need to be performed to evaluate the failure rate with only batteries A and B. From the Kaplan-Meier curve (Figure 1 ), an inspection of only battery A (blue line) indicates that a 10% failure would occur somewhere near 1,000 days (almost 3 years). A future analysis with a different mix of battery suppliers could change the recommended replacement interval.
Analysis Comparing Battery Cost
Certain assumptions about the costs involved when replacing an unexpected failure versus a planned replacement will need to be made. An unexpected battery failure would be assumed to cost more due to the additional labor time involved. An unplanned battery failure will cost $80 for the battery, plus an estimated $60 in labor time split among nursing staff, equipment cleaning personnel, and clinical engineering technicians. Battery replacement performed during the regular annual maintenance at the two-or three-year mark results in an additional $80 for the battery and $10 in labor. The cost analysis assumes that the infusion pumps will be replaced with new models soon after the ninth year of use.
Replacing batteries during three-year maintenance:
where N is the number of devices using the battery, TY is the total life expectancy in years, MI is the maintenance interval in years, PM is the cost to replace a battery during a routine maintenance, FB is the cost to replace a battery if it fails during use, B is the cost of the battery, L1 is the labor cost to replace the battery during maintenance, L2 is Therefore, to reduce the risk of failure between the second and third year, an increased annual cost of $5,341 would be needed. For this minimal increase in expenditure, a significant increase in reliability is gained, as the cumulative estimate of unexpected battery failures decreases from 28% to 7%. This minimal increase in cost would eliminate the estimated 93 battery failures between the second and third year.
Although this recommendation appears reasonable, it would need to be proposed to the executive risk managers at the facility to determine how the reduction in risk of battery failure would translate into reduced risk of harm to the patient. A single incident of serious patient harm prevented over the life of the infusion devices would be of such magnitude that the $5,341 increase in annual cost could be considered insignificant. However, if other measures are in place that reduce the risk of patient harm due to battery failure, the additional cost may not be justifiable. Other unexplored factors, such as available technician time or cost of renting additional infusion devices, may justify the battery maintenance cost. This type of analysis provides valuable information to aid medical device management and executive staff in reaching a decision.
Conclusion
Certain assumptions important to this analysis were based on the three batteries studied, labor time and associated costs, and how the one hospital in question managed battery charging. The data showed a significant difference in lifespan for the vendor C battery when compared with the infusion device manufacturer's battery, but available data were not sufficient to determine whether the other supplier's battery was statistically different from that of the manufacturer. A potentially useful reduction in risk of failure (from 28% to 7%), at an increased annual cost of about $5,400, also was revealed. This analysis would likely be repeated every couple years at the same facility to determine whether any new changes would be warranted. These results are not directly transferable to other facilities due to the differences in how infusion device batteries are maintained; however, the analytic methods used are applicable to other medical facilities. n
